

# INPLASY PROTOCOL

To cite: Li et al. Efficacy and Safety of Photodynamic Therapy for Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Inplasy protocol 2022110043. doi: 10.37766/inplasy2022.11.0043

Received: 09 November 2022

Published: 10 November 2022

**Corresponding author:**  
Gongwei Long

longgw1996@163.com

**Author Affiliation:**  
National Cancer Center, Cancer Hospital Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.

**Support:** NA.

**Review Stage at time of this submission:** Preliminary searches.

**Conflicts of interest:**  
None declared.

## Efficacy and Safety of Photodynamic Therapy for Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis

Li, HT<sup>1</sup>; Long, GW<sup>2</sup>; Tian, J<sup>3</sup>.

**Review question / Objective:** To comprehensively summarize the relevant clinical studies, and assess the efficacy and safety of PDT in the treatment of NMIBC.

**Eligibility criteria:** (1) pathologically confirmed NMIBC; (2) included > 5 patients who received PDT; (3) clinical studies including randomized-controlled trials, case-control studies, and single-arm reports; (4) included efficacy and/or safety results; (5) follow-up duration > 6 months; (6) report was written in English or has an English abstract.

**INPLASY registration number:** This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 10 November 2022 and was last updated on 10 November 2022 (registration number INPLASY2022110043).

### INTRODUCTION

**Review question / Objective:** To comprehensively summarize the relevant clinical studies, and assess the efficacy and safety of PDT in the treatment of NMIBC.

**Condition being studied:** Bladder cancer.

### METHODS

**Participant or population:** Non-muscle-invasive bladder cancer (NMIBC).

**Intervention:** Photodynamic therapy (PDT).

---

**Comparator:** Standard care, if Comparator exists.

**Study designs to be included:** clinical studies including randomized-controlled trials, case-control studies, and single-arm reports.

**Eligibility criteria:** (1) pathologically confirmed NMIBC; (2) included > 5 patients who received PDT; (3) clinical studies including randomized-controlled trials, case-control studies, and single-arm reports; (4) included efficacy and/or safety results; (5) follow-up duration > 6 months; (6) report was written in English or has a English abstract.

**Information sources:** PubMed, Web of Science, and Scopus.

**Main outcome(s):** Safety and efficacy.

**Quality assessment / Risk of bias analysis:** Using Cochrane risk of bias (RoB 2) tool and the ROBINS- I tool

**Strategy of data synthesis:** A fixed-effects model was used to calculate the pooled estimates if no significant heterogeneity was identified ( $I^2 < 50\%$ ). Otherwise, a random-effects model was used.

**Subgroup analysis:** According to T stage, grade, risk, photosensitizer.

**Sensitivity analysis:** A sensitivity analysis was also performed by changing the effect model.

**Language restriction:** Report was written in English or has a English abstract.

**Country(ies) involved:** China.

**Keywords:** photodynamic therapy; bladder cancer.

**Contributions of each author:**

Author 1 - Haitao Li.

Author 2 - Gongwei Long.

Author 3 - Jun Tian.